ICON plc | Clinical Research Organisation (CRO) for Drug Development

Natural history studies to improve drug development in rare diseases

Rare disease drug development is challenging due to limited info on patient distribution, change in disease progression and relevant outcomes to define treatment benefits.

Practical considerations for decentralised & hybrid clinical trials

Making the transition.

Unlocking the potential of advanced therapies developed for rare diseases

How to leverage regulatory strategies and interactions with the EU EMA and the U.S. FDA to accelerate development

Spotlight on regulatory reforms in China

A guide to the evolving regulatory environment.

Webinars

Upcoming webinar: Decentralised Clinical Trials - regulatory and legal considerations for clinical data

9 May 2022 - Register today

Watch the webinar: A guide to conducting clinical trials in China

Access webinar recording.

Watch the webinar: Tools of the trade for patient-centric clinical development

Access webinar recording.

On-demand webinars

Visit our webinar channel to access other recent webinars.

Featured Services

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.�

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

14 May 2022

My Clinical Research story – Lisa Linn

ICON's Lisa Linn shares their personal experience with clinical trials.

14 May 2022

My Clinical Research story – Jill Doherty

ICON's Jill Doherty shares their personal experience with clinical trials.

13 May 2022

My Clinical Research story – Ellen Dalbo

ICON's Ellen Dalbo shares their personal experience with clinical trials.

13 May 2022

Clinical Trials Day – Employee Testimonials

ICON's Ben Prabhu, Amber Hallenborg, Shannon Jonietz, Rebekah Nolan, Kim Pope, and Agustina Mazza share their personal experience with clinical trials.

11 May 2022

How joint venture models can boost Japan’s pharmaceutical industry

Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.

27 April 2022

NICE guidance on real-world evidence to usher innovative treatments

NICE published new guidance to give patients early access to innovative treatments by allowing greater flexibility considering a broader evidence base, making it easier for innovative and promising treatments to reach the patient incorporating the usage of real-world evidence.

21 March 2022

Sharing my Down syndrome story - Beverly Romero

Beverly Romero tells the story of her son Oliver.

25 January 2022

Progressive IVDR rollout made official

In the fall of 2020, the European Commission issued a proposal to modify the implementation timeline for the new In Vitro Diagnostic Medical Devices Regulation (IVDR). Now, as of 15 December 2021, the European Parliament and the European Council have adopted this proposal, making the suggested progressive IVDR rollout timeline official.

07 January 2022

Combatting AMR with new tools to diagnose and treat infectious disease

The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia has been a transformative medical achievement.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Healthcare Intelligence

The evolution of FSP: not just for large pharma

Best practices to increase engagement with medical and scientific poster content

Ensuring scientific rigor in external control arms